Organisation paid for research Program year 2025 Source: CMS Open Payments

Qcca Network, LLC

Neither a doctor nor a teaching hospital

Research payments

$1,259,429

233 payments

Through program year 2025, Qcca Network, LLC is reported as receiving $1,259,429 in research payments, across 233 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $484,790 142
2024 Research $576,025 86
2022 Research $167,682 3
2021 Research $30,932 2

Breakdown

Who paid Research payments · program years 2021–2025
  1. Eli Lilly and Company $752,344 23 payments
  2. Aveo Pharmaceuticals, Inc. $331,061 186 payments
  3. Janssen Research & Development, LLC $176,024 24 payments
Studies the money was for Research payments · program years 2021–2025
  1. TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor $331,061 186 payments
  2. A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (Loxo-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin-Cll-314) $208,166 5 payments
  3. A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (Loxo-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin Cll-322) $171,695 7 payments
  4. Study of Loxo-305 Versus Investigator's Choice (Idelar Or Br) in Patients With Previously Treated Chronic Lymphocytic Leukemia (Cll)/Small Lymphocytic Lymphoma (SLL) (Bruin Cll-321) $169,111 4 payments
  5. A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd $140,079 15 payments
  6. Emonarcher: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, Her2+ Early Breast Cancer Who Have Completed Adjuvant Her2-Targeted Therapy $115,000 1 payment
  7. Ember-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant VS Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for Er+, Her2- Early Breast Cancer With An Increased Risk of Recurrence $76,138 3 payments
  8. Acebreast03 $19,624 7 payments
  9. Ace-Breast-03 $16,321 2 payments
  10. A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (Loxo-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin Cll-322) $10,450 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record